What are the side effects of antipsychotic medications, including typical (first‑generation) and atypical (second‑generation) agents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Antipsychotic Side Effects: A Comprehensive Overview

Antipsychotic medications produce a wide array of adverse effects that differ substantially between individual agents, with typical (first-generation) antipsychotics primarily causing extrapyramidal symptoms and tardive dyskinesia, while atypical (second-generation) antipsychotics more commonly cause metabolic complications including weight gain, diabetes, and dyslipidemia 1, 2.

Critical Distinction: Individual Drug Profiles Matter More Than Class

The classification of antipsychotics into "typical" versus "atypical" is misleading and clinically unhelpful 3. Side effect profiles are specific to each medication and do not neatly fit into first- and second-generation classifications 2, 4. You must evaluate each antipsychotic individually based on its unique receptor binding profile and resulting adverse effect pattern.

Major Side Effect Categories by Drug Class

Typical (First-Generation) Antipsychotics

High-potency agents (haloperidol, fluphenazine, thiothixene):

  • Extrapyramidal symptoms are the predominant concern 5
  • Acute dystonia (sudden muscle spasms, oculogyric crisis, laryngospasm - potentially life-threatening)
  • Drug-induced parkinsonism (bradykinesia, tremors, rigidity)
  • Akathisia (severe restlessness, often misinterpreted as psychotic agitation)
  • Tardive dyskinesia risk: 50% of elderly patients after 2 years of continuous use 6

Low-potency agents (chlorpromazine, thioridazine):

  • Prominent anticholinergic effects (sedation, memory deficits, dry mouth, constipation)
  • Cardiovascular effects (orthostatic hypotension, QTc prolongation)
  • Less extrapyramidal symptoms than high-potency agents 5

Atypical (Second-Generation) Antipsychotics

The critical advantage is diminished extrapyramidal symptom risk compared to typical agents 6, but this comes with different serious concerns:

Metabolic syndrome cluster (especially clozapine and olanzapine):

  • Extreme weight gain - this is the most common significant problem in clinical practice 5, 2
  • Type 2 diabetes mellitus
  • Dyslipidemia
  • Cardiovascular disease risk 4, 7

Drug-specific profiles:

  • Clozapine: Agranulocytosis (1%, potentially fatal), seizures (3%, dose-dependent), hypersalivation, sedation, myocarditis 5, 4

  • Olanzapine: Highest metabolic risk after clozapine, significant weight gain 8, 7

  • Risperidone/Paliperidone: Hyperprolactinemia (highest among atypicals), sexual dysfunction, extrapyramidal symptoms at doses ≥2mg/day 6, 5, 7

  • Quetiapine: Sedation, transient orthostatic hypotension 6

  • Aripiprazole: Akathisia, but protective against weight gain and metabolic effects when combined with other antipsychotics 9, 8

Universal Antipsychotic Risks (All Agents)

All antipsychotics carry these risks regardless of generation 4:

  • Sedation
  • Sexual dysfunction
  • Postural hypotension
  • Cardiac arrhythmias and QTc prolongation
  • Sudden cardiac death
  • Neuroleptic malignant syndrome (rare but life-threatening)

Special Populations: Children and Adolescents

Youth are at higher risk for certain side effects and may have difficulty communicating concerns 5:

  • Higher risk for extrapyramidal symptoms than adults 5
  • Younger, antipsychotic-naive children face increased weight gain risk 10
  • Acute dystonia risk factors: young age, male gender, high-potency agents 5

Management Algorithm

Step 1: Prevention

  • Use the lowest effective dose
  • Avoid typical antipsychotics when possible due to tardive dyskinesia risk 6
  • Obtain baseline measurements: weight, metabolic parameters, movement assessment (AIMS scale) 5

Step 2: Monitoring Schedule

  • Movement disorders: assess every 3-6 months with AIMS 5
  • Weight and metabolic parameters: regular monitoring, especially with clozapine/olanzapine
  • Clozapine requires weekly CBC for 6 months, then biweekly 5

Step 3: When Side Effects Occur

If the antipsychotic is providing substantial benefit and the adverse effect is not life-threatening:

  1. First choice: Lower the dose or adjust dosing schedule 2
  2. Second choice: Switch to a different antipsychotic with a different receptor profile 1, 2
  3. Consider behavioral interventions where applicable
  4. Add concomitant medications when necessary (though generally not desirable) 2

Step 4: Specific Interventions

  • Acute dystonia: Anticholinergic or antihistaminic medications (highly effective) 5
  • Parkinsonism: Anticholinergics or amantadine 5
  • Akathisia: Lower dose if feasible; β-blockers or benzodiazepines (anticholinergics inconsistently helpful) 5
  • Weight gain: Metformin (especially with clozapine) 1, 2
  • Tardive dyskinesia: Discontinue or switch medication; valbenazine or deutetrabenazine (clinical utility unclear) 2
  • Hypersalivation: Anticholinergic drops applied sublingually 2

Critical Pitfalls to Avoid

Do not use prophylactic anticholinergics routinely - reserve for high-risk patients (young males on high-potency agents, history of dystonic reactions) 5. Avoid benztropine or trihexyphenidyl in elderly patients with typical antipsychotics 6.

Do not assume all atypicals are metabolically safe - clozapine and olanzapine carry the highest metabolic risk, comparable to or exceeding typical agents 8, 7.

Do not ignore akathisia - it is commonly misinterpreted as psychotic agitation or anxiety and is a major cause of medication non-compliance 5.

Do not continue typical antipsychotics long-term without compelling reason - the 50% tardive dyskinesia risk in elderly patients after 2 years is unacceptable when alternatives exist 6.

When to Switch Medications

Switch if 1, 2:

  • Life-threatening adverse effects occur (agranulocytosis, NMS, severe dystonia)
  • Intolerable side effects persist despite dose reduction
  • Tardive dyskinesia develops (unless patient is in full remission and any change risks relapse) 5
  • Metabolic complications emerge that cannot be managed

The decision to continue versus switch must weigh relapse risk against side effect burden - this requires individualized assessment of disease severity, treatment response, and patient preference 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.